CHMP3 promotes the progression of hepatocellular carcinoma by inhibiting caspase‑1‑dependent pyroptosis

Zheng,Yuting; Zheng,Yuting; Yang,Shaojie; Yang,Shaojie; Dai,Wanlin; Dai,Wanlin; Wang,Jingnan; Wang,Jingnan; Bi,Shiyuan; Bi,Shiyuan; Zhang,Xiaolin; Zhang,Xiaolin; Zheng,Zhuyuan; Zheng,Zhuyuan; Sun,Yang; Sun,Yang; Wu,Shuodong; Wu,Shuodong; Kong,Jing; Kong,Jing

doi:10.3892/ijo.2023.5596

CHMP3 promotes the progression of hepatocellular carcinoma by inhibiting caspase‑1‑dependent pyroptosis

Authors:
- Yuting Zheng
- Shaojie Yang
- Wanlin Dai
- Jingnan Wang
- Shiyuan Bi
- Xiaolin Zhang
- Zhuyuan Zheng
- Yang Sun
- Shuodong Wu
- Jing Kong
View Affiliations

Affiliations: Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Innovation Institute of China Medical University, Heping, Shenyang, Liaoning 110122, P.R. China
Published online on: November 30, 2023 https://doi.org/10.3892/ijo.2023.5596
Article Number: 8
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Charged multivesicular body protein 3 (CHMP3) is an elemental constituent of the endosomal sorting complex required for transport (ESCRT) III, whose function as a tumor susceptibility gene in the development of liver cancer remains unclear. CHMP3 was found to be associated with pyroptosis by bioinformatics analysis of data from patients with hepatocellular carcinoma (HCC) in The Cancer Genome Atlas database. It was aimed to explore the role and potential mechanisms of CHMP3 in the development of liver cancer. The expression of CHMP3 at the tissue level was examined using immunohistochemistry and western blot analysis. Subsequently, HepG2 and Huh‑7 cells were transfected with small interfering RNA and overexpression plasmids to change CHMP3 expression. The proliferative capacity of cells was examined using colony formation and Cell Counting Kit‑8 assays. Wound healing and Transwell assays were used to examine the migratory and invasive abilities of the cells. Transmission electron microscopy was used to observe changes in cell morphology. Western blotting was used to examine the expression of caspase‑1 signaling pathway related proteins, a classic pathway of pyroptosis. In addition, a xenograft tumor model was used to examine the tumorigenic ability of CHMP3 in vivo. The results demonstrated that CHMP3 expression was upregulated in HCC and was associated with poor prognosis. Knockdown or overexpression of CHMP3 inhibited or promoted the proliferation, migration and invasion of liver cancer cells. Knockdown of Huh‑7 showed changes in cell membrane integrity as well as cytoplasmic leakage. Furthermore, knockdown of CHMP3 may activate the caspase‑1 pyroptosis signaling pathway which in turn inhibits the progression of liver cancer, and this effect can be reversed by the caspase‑1 inhibitor AYC. In conclusion, CHMP3 may affect the development of liver cancer through the caspase‑1‑mediated pyroptosis pathway.

View Figures

View References

1	Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, et al: Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: Diagnostic accuracy of 3D quantitative image analysis. Radiology. 273:746–758. 2014.
2	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
3	Tao S, Liang S, Zeng T and Yin D: Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Front Immunol. 13:10436672023.
4	Glantzounis GK, Paliouras A, Stylianidi MC, Milionis H, Tzimas P, Roukos D, Pentheroudakis G and Felekouras E: The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. Eur J Surg Oncol. 44:195–208. 2018.
5	Cammarota A, Zanuso V, Manfredi GF, Murphy R, Pinato DJ and Rimassa L: Immunotherapy in hepatocellular carcinoma: How will it reshape treatment sequencing? Ther Adv Med Oncol. 15:175883592211480292023.
6	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
7	Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, Yu T, Wu X, Shi Y, Ma P and Shu Y: Pyroptosis: A new frontier in cancer. Biomed Pharmacother. 121:1095952020.
8	Ouyang X, Zhou J, Lin L, Zhang Z, Luo S and Hu D: Pyroptosis, inflammasome, and gasdermins in tumor immunity. Innate Immun. 29:3–13. 2023.
9	Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F and Shao F: Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 526:660–665. 2015.
10	Vande Walle L and Lamkanfi M: Pyroptosis. Curr Biol. 26:R568–R572. 2016.
11	Yu P, Zhang X, Liu N, Tang L, Peng C and Chen X: Pyroptosis: Mechanisms and diseases. Signal Transduct Target Ther. 6:1282021.
12	Kang R, Zeng L, Zhu S, Xie Y, Liu J, Wen Q, Cao L, Xie M, Ran Q, Kroemer G, et al: Lipid peroxidation drives gasdermin D-mediated pyroptosis in lethal polymicrobial sepsis. Cell Host Microbe. 24:97–108.e4. 2018.
13	Pilla DM, Hagar JA, Haldar AK, Mason AK, Degrandi D, Pfeffer K, Ernst RK, Yamamoto M, Miao EA and Coers J: Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS. Proc Natl Acad Sci USA. 111:6046–6051. 2014.
14	Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Huai W, Qiu Y, Li T, Ma X, Liu Y, et al: Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome. Lab Invest. 95:804–816. 2015.
15	Lata S, Schoehn G, Solomons J, Pires R, Göttlinger HG and Weissenhorn W: Structure and function of ESCRT-III. Biochem Soc Trans. 37:156–160. 2009.
16	Babst M, Katzmann DJ, Estepa-Sabal EJ, Meerloo T and Emr SD: Escrt-III: An endosome-associated heterooligomeric protein complex required for mvb sorting. Dev Cell. 3:271–282. 2002.
17	Babst M, Wendland B, Estepa EJ and Emr SD: The Vps4p AAA ATPase regulates membrane association of a Vps protein complex required for normal endosome function. Embo J. 17:2982–2993. 1998.
18	Bishop N and Woodman P: ATPase-defective mammalian VPS4 localizes to aberrant endosomes and impairs cholesterol trafficking. Mol Biol Cell. 11:227–239. 2000.
19	Saksena S, Wahlman J, Teis D, Johnson AE and Emr SD: Functional reconstitution of ESCRT-III assembly and disassembly. Cell. 136:97–109. 2009.
20	Teis D, Saksena S and Emr SD: Ordered assembly of the ESCRT-III complex on endosomes is required to sequester cargo during MVB formation. Dev Cell. 15:578–589. 2008.
21	Wang Z and Wang X: miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling. J Cell Physiol. 235:2825–2835. 2020.
22	Zhou Y, Zheng J, Bai M, Gao Y and Lin N: Effect of pyroptosis-related genes on the prognosis of breast cancer. Front Oncol. 12:9481692022.
23	Niu D, Chen Y, Mi H, Mo Z and Pang G: The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. Front Genet. 13:9744162022.
24	Li C, Liang H, Bian S, Hou X and Ma Y: Construction of a prognosis model of the pyroptosis-related gene in multiple myeloma and screening of core genes. ACS Omega. 7:34608–34620. 2022.
25	Li Y, Li Y, Zhang X, Duan X, Feng H, Yu Z and Gao Y: A novel association of pyroptosis-related gene signature with the prognosis of hepatocellular carcinoma. Front Oncol. 12:9868272022.
26	Man SM and Kanneganti TD: Regulation of inflammasome activation. Immunol Rev. 265:6–21. 2015.
27	Kovacs SB and Miao EA: Gasdermins: Effectors of pyroptosis. Trends Cell Biol. 27:673–684. 2017.
28	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017.
29	Liu L, Li Y, Cao D, Qiu S, Li Y, Jiang C, Bian R, Yang Y, Li L, Li X, et al: SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition. Cancer Lett. 510:93–104. 2021.
30	Jia C, Chen H, Zhang J, Zhou K, Zhuge Y, Niu C, Qiu J, Rong X, Shi Z, Xiao J, et al: Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 67:311–318. 2019.
31	Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X, Zhao W, Huai W, Guo P and Han L: Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest. 94:52–62. 2014.
32	Yan Z, Da Q, Li Z, Lin Q, Yi J, Su Y, Yu G, Ren Q, Liu X, Lin Z, et al: Inhibition of NEK7 suppressed hepatocellular carcinoma progression by mediating cancer cell pyroptosis. Front Oncol. 12:8126552022.
33	Chen W, Quan Y, Fan S, Wang H, Liang J, Huang L, Chen L, Liu Q, He P and Ye Y: Exosome-transmitted circular RNA hsa_circ_0051443 suppresses hepatocellular carcinoma progression. Cancer Lett. 475:119–128. 2020.
34	Zhang Q, Chen L, Gao M, Wang S, Meng L and Guo L: Molecular docking and in vitro experiments verified that kaempferol induced apoptosis and inhibited human HepG2 cell proliferation by targeting BAX, CDK1, and JUN. Mol Cell Biochem. 478:767–780. 2023.
35	Sun X, Zhong X, Ma W, Feng W, Huang Q, Ma M, Lv M, Hu R, Han Z, Li J and Zhou X: Germacrone induces caspase-3/GSDME activation and enhances ROS production, causing HepG2 pyroptosis. Exp Ther Med. 24:4562022.
36	Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, Nie L, Chen Y, Wang YC, Liu C, et al: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 22:1264–1275. 2020.
37	Zhang T, Li Y, Zhu R, Song P, Wei Y, Liang T and Xu G: Transcription factor p53 suppresses tumor growth by prompting pyroptosis in non-small-cell lung cancer. Oxid Med Cell Longev. 2019:87468952019.
38	Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, Li X, Yang J, Xiang B and Yi M: Pyroptosis: A new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 40:1532021.
39	Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF, Cheng KC, Teng YN, Lin YH, Yen CH and Chiu CC: Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 11:8813–8835. 2021.
40	Cui J, Zhou Z, Yang H, Jiao F, Li N, Gao Y, Wang L, Chen J and Quan M: MST1 suppresses pancreatic cancer progression via ROS-induced pyroptosis. Mol Cancer Res. 17:1316–1325. 2019.
41	Teng JF, Mei QB, Zhou XG, Tang Y, Xiong R, Qiu WQ, Pan R, Law BY, Wong VK, Yu CL, et al: Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer. Cancers (Basel). 12:1932020.
42	Rébé C and Ghiringhelli F: Interleukin-1β and cancer. Cancers (Basel). 12:17912020.
43	Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT and Tsung A: High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 55:1863–1875. 2012.
44	Lopez-Pastrana J, Ferrer LM, Li YF, Xiong X, Xi H, Cueto R, Nelson J, Sha X, Li X, Cannella AL, et al: Inhibition of caspase-1 activation in endothelial cells improves angiogenesis: A NOVEL THERAPEUTIC POTENTIAL FOR ISCHEMIA. J Biol Chem. 290:17485–17494. 2015.
45	He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, Wang Y, Liu D, Xie M, Ji X, et al: IL-1β-induced elevation of solute carrier family 7 member 11 promotes hepatocellular carcinoma metastasis through up-regulating programmed death ligand 1 and colony-stimulating factor 1. Hepatology. 74:3174–3193. 2021.
46	Dang Y, Chen J, Feng W, Qiao C, Han W, Nie Y, Wu K, Fan D and Xia L: Interleukin 1β-mediated HOXC10 overexpression promotes hepatocellular carcinoma metastasis by upregulating PDPK1 and VASP. Theranostics. 10:3833–3848. 2020.
47	Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Pöschinger T, Kiessling F and Ries CH: Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma. Hepatology. 70:1280–1297. 2019.
48	Shen Z, Zhou H, Li A, Wu T, Ji X, Guo L, Zhu X, Zhang D and He X: Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. Aging (Albany NY). 13:22120–22133. 2021.
49	Rühl S, Shkarina K, Demarco B, Heilig R, Santos JC and Broz P: ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science. 362:956–960. 2018.
50	Tang Q, Li W, Zheng X, Ren L, Liu J, Li S, Wang J and Du G: MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduct Target Ther. 5:2792020.
51	Bruix J, Gores GJ and Mazzaferro V: Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 63:844–855. 2014.
52	Kuphal S and Bosserhoff AK: Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene. 25:248–259. 2006.
53	Mondal S, Adhikari N, Banerjee S, Amin SA and Jha T: Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem. 194:1122602020.
54	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011.
55	Walker A, Frei R and Lawson KR: The cytoplasmic domain of N-cadherin modulates MMP-9 induction in oral squamous carcinoma cells. Int J Oncol. 45:1699–1706. 2014.
56	Cao ZQ, Wang Z and Leng P: Aberrant N-cadherin expression in cancer. Biomed Pharmacother. 118:1093202019.